Novel Anti-Cancer Drug, ONC201, Focus of Alliance Between Oncoceutics and MD Anderson

Oncoceutics Inc. and The University of Texas MD Anderson Cancer Center today announced the initiation of a strategic alliance and research collaboration agreement for the clinical development of ONC201, a novel anti-cancer drug.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news